Mutations in the MUT locus encoding for the methylmalonyl-CoA mutase (MCM) apoenzyme are responsible for the mut forms of methylmalonic acidemia (MMA). To date, 49 different mutations have been identified in mut MMA. Only two frequent mutations have been reported in the Japanese population and in AfricanAmericans. Here we report a new missense mutation N219Y (731 A?T) which we found in five unrelated families of French and Turkish descent. All the patients exhibited a severe mut8 phenotype and three of them were homozygotes for N219Y. Direct involvement of the mutation in the loss of enzyme activity was demonstrated by mutagenesis and transient expression study. Mapping of the mutation onto a threedimensional model of human MCM constructed by homology with the Propionibacterium shermanii enzyme shows that it lies in a highly conserved secondary structure motif and might suggest impaired folding and/or poor stability compatible with the mut8 phenotype. Finally, a 1% N219Y carrier frequency was observed in a French anonymous control population. Thus, N219Y is the first frequent mut mutation to be reported in the Caucasian population.
Introduction
Methylmalonic acidemia (MMA; MIM#251000) is an autosomal recessive inherited inborn error of metabolism that results from the functional impairment of methylmalonylCoA mutase (MCM, EC 5.4.99.2). MCM is a mitochondrial nuclear-encoded homodimer enzyme responsible for the conversion of L-methylmalonyl-CoA to succinyl-CoA in the propionyl-CoA catabolic pathway toward the Krebs cycle. Each monomer binds one molecule of adenosylcobalamin, a vitamin B 12 derivative and the cofactor of the enzymatic reaction.
MMA is a heterogeneous condition in which the mut forms (incidence estimated 1/30 000 to 1/50 000) are due to MCM apoenzyme deficiency. Studies on fibroblasts from patients with mut MMA have distinguished variant forms with undetectable residual MCM activity (designated mut8) and forms with hydroxocobalamin-dependent residual activity (designated mut molecular analysis of mut MMA has revealed at least 49 different mutations 3 ± 7 demonstrating the highly pleiomorphic nature of this condition. Only two mutations are frequent: the first one (G717V) in African-Americans 8 and the second (E117X) in the Japanese population. 9, 10 A three-dimensional model of the human MCM structure 11 has been deduced from the crystal structure of the corresponding enzyme in Propionibacterium shermanii, that shares 65% sequence identity with human MCM. 12 The model divides the molecule into two major domains: (i) a N-terminal eightstranded b/a barrel including the CoA moiety binding site and the dimer interface, and (ii) a C-terminal a/b domain with five parallel b strands encompassing the`B 12 -binding domain'. Availability of this model allows molecular modeling of the potential structural effects of the observed mutations.
Here, we report a novel missense mutation N219Y which, unexpectedly, was found in five independent mut8 Caucasian families. Site-directed mutagenesis and transient expression show that the observed nucleotide variation is indeed the causative mutation of the enzymatic defect. The affected asparagine residue is conserved among species and lies in a highly conserved secondary structure motif. Molecular modelling suggests that substitution by a tyrosine is likely to result in impaired folding and/or poor stability of the MCM molecule, compatible with the mut8 phenotype.
Patients and methods

Patients
We have investigated five unrelated patients affected with B12-unresponsive MMA. Patient 1 was the first child of consanguineous Turkish parents. He presented with acute metabolic acidosis at 3 months of age. However poor feeding and mild dehydration had been observed at 4 days of age. It was attributed to sepsis at this time but this was not documented and it could well have been the very first symptoms of the disease. His low protein diet consisted of 1 g/kg/d of protein, ie about 800 mg/d of valine. The patient died at 30 months of age following an acute decompensation. The four other patients were all born to French non consanguineous parents.
Patient 2 is affected with a neonatal onset form. She is presently 4 years old and has experienced six intercurrent decompensations. At Mutation detection MCM cDNA was prepared from cultured fibroblasts according to standard procedures.
14 RT ± PCR products obtained with the primers described by Ogasawara 9 were directly sequenced on an ABI 310 automatic sequencer (Perkin Elmer, Foster City, CA, USA) using the Dye Terminator method, without the secondary nested-PCR included in the original procedure. To confirm the homozygous state of the N219Y mutation, the sequence of exon 3 was determined on genomic DNA using primers described by Adjalla. 4 Moreover, to confirm the N219Y mutation by a second independent procedure and to screen a control population, a new PCR forward primer with a single base substitution was designed (primer 3mut, see legend to Figure 1 ) so as to create a NdeI restriction site when the mutation is present. Digestion of PCR-amplifed products from genomic DNA was performed according to the manufacturer's instructions (New England Biolabs, Beverly, MA, USA) and the resulting fragments analysed by electrophoresis on a 8% polyacrylamide gel.
Transient expression study
Firstly, a stable mut8 cell line (SCK2) was obtained by transforming MCM-deficient fibroblasts from patient 1 by the pLASwt plasmid (a gift from Prof A Fisher), that contains SV40 DNA encompassing the entire early region with a defective origin of replication. 15 Fibroblasts were transfected by electroporation with a Gene Pulser (Biorad Laboratories, Hercules, CA, USA), using 4.10 6 primary cultured cells, 4 mg of pLASwt plasmid, and a 250 V pulse at a capacitance of 1600 mF. The SCK2 cell line was used for transient expression analysis. Secondly, the 731 A?T substitution was introduced by sitedirected mutagenesis (USE Mutagenesis Kit ± Amersham N219Y mutation in MMA Caucasian patients C Acquaviva et al 578 Pharmacia Biotech, Amersham, UK) into an expression vector, pCMVmut (constructed by R Touraine), containing the wild-type MCM cDNA downstream from the CMV promoter. Direct sequencing and enzymatic restriction were used to confirm the presence of the mutation in the recombinant plasmid (pCMVmut731A?T).
SCK2 cells were transfected using the Superfect reagent (Qiagen, Chatsworth, CA, USA) with: (i) the wild-type expression vector (pCMVmut) as a positive control; (ii) a vector containing a stop codon at position 238 (pCMVmutNSCD238) in the beginning of the coding sequence as a negative control; and (iii) pCMVmut731A?T. MCM activity was monitored 48 h after transfection, using the [ 14 C]-propionate incorporation method. All the experiments were carried out three times independently and in duplicate.
Haplotypes Several microsatellite markers surrounding MUT on the short arm of the chromosome 6 were PCR-amplified and analysed on the ABI 310 sequencer. They included: D6S1714, D6S243, D6S465, D6S1669, and D6S1632.
MCM structural modelisation
To construct the three-dimensional structure of human MCM, molecular modelling simulations were performed with the MODELLER 4.0 software 16 using the experimental structure of P. shermanii MCM (Protein Data Bank accession code: 1REQ). As notified in Thoma È and Leadlay, 11 the very high amino-acid sequence identity between human MCM and the a subunit of the P. shermanii enzyme allowed the construction of a 3D model that satisfies spatial constraints.
Results
All the patients' fibroblasts presented with a marked decrease in MCM enzyme activity, ie, less than 10% of the controls ( Table 1) . As activity is measured with an excess of cofactor (adenosylcobalamin concentration above 100 K m ), this indicates that the defect indeed affects the apoenzyme and not the cofactor and that all the patients belong to the mut type. Similarly, propionate incorporation was drastically reduced in all cases and there was no correlation between added exogenous hydroxocobalamin and propionate uptake (Table  1) . Altogether these data define a typical mut8 MMA phenotype.
Comparison of DNA sequences obtained for the patients with the consensus sequence of the human MCM cDNA (Genebank, accession number M65022) revealed a novel single nucleotide substitution in MUT exon 3. It consists of an A?T transversion at position 731 in the cDNA. This change was confirmed by sequence determination and restriction analysis of PCR products from genomic DNA (Figure 1 ). Three patients were homozygotes for the substitution (patients 1 ± 3) and two patients were heterozygotes (patients 4 and 5). As expected, for each homozygous patient, the parents are heterozygotes for the substitution (data not shown). Restriction analysis was also used to screen DNAs from two different control populations for the 731 A?T substitution: in a population of 105 anonymous mentally retarded children and in a control population of 100 anonymous normal children; it was found in the heterozygous state in two individuals from the first population.
For patients 4 and 5, a second sequence modification has been found. It consists in a G?A transition at position 399 and a G?T transition at position 549 in the cDNA, respectively. Interestingly, the 731 A?T substitution was found on chromosomes with various haplotypes. Indeed, except for the Turkish patient who was homozygote for all the studied markers, all the other patients including the two homozygotes for the 731 A?T substitution were heterozygotes for the microsatellite haplotype surrounding MUT.
At the protein level, the 731 A?T, 399 G?A, 549 G?T substitutions result respectively in the replacement of an asparagine residue by a tyrosine at position 219 (N219Y), an Figure 1 Detection of the 731A?T substitution by NdeI restriction. Genomic DNA was PCR-amplified using the 3mut forward primer (5' ARC TTA CTG GTA CCA TCC CA 3') localised just upstream from nucleotide 731 in exon 3. This primer contains a single nucleotide substitution (the underlined bold C) so as to create a NdeI restriction site when the 731A?T substitution is present. The reverse primer was that described by Adjalla et al 4 for this exon. The products of NdeI digestion were analysed by electrophoresis on a 8% polyacrylamide gel. Wildtype sequence derived from a normal control (lane 1) gives a 166 bp fragment. DNA from homozygous patients for the 731A?T substitution are cleaved by NdeI giving rise to a 146 pb fragment (lanes 2, 3, 4). In heterozygous patients, the two fragments are observed (lanes 5 and 6). arginine residue by a histidine at position 108 (R108H) and a glycine residue by a valine at position 158 (G158V). All this residues are conserved from bacteria to mouse and man, thus, although the R108H and G158V substitutions have not been studied functionally, it is likely that they represent the second deleterious mutation in patients 4 and 5.
In the MCM primary structure, Asn219 is located in an amino-acid stretch that shows a particularly high level of homology between species (Figure 2) . Mapping of the N219Y substitution on the three-dimensional model of human MCM 11 shows that Asn219 is located in the fourth b-strand of the N-terminal eight-stranded b/a barrel, ie, a specific N219Y mutation in MMA Caucasian patients C Acquaviva et al 580 secondary structure motif of the molecule (Figure 3) . However, it does not appear to have direct interaction with the substrate as its side chain is turned outside of the b-barrel and buried by one of the surrounding a-helices.
To determine if the 731 A?T substitution was indeed responsible for the deficient phenotype, we performed transient expression studies in SCK2, a mut8 cell line immortalised from the fibroblasts of patient 1. As expected, transfection of the wild-type expression vector (pCMVmut) resulted in an increased propionate incorporation by SCK2 cells (Figure 4) . In contrast, transfection of the vector containing the 731 A?T substitution (pCMVmut731A?T) did not change propionate incorporation over the background value measured after transfection with pCMVmutNSCD238, a vector in which MCM cDNA contains a null mutation.
Discussion
Here, we report a novel mutation in the MUT gene which we observed in five independent Caucasian families with MMA. Insertion of this mutation in a wild-type MCM expression vector abolishes its ability to restore enzyme activity in a MCM-deficient cell line. Thus N219Y is indeed the causative mutation of the patients' mut8 phenotype. Residual MCM activity was very low in the patients' fibroblasts and all the patients were affected with a severe clinical form and a low valine tolerance (5800 mg/d). All experienced acute intercurrent decompensations and one was lethal in one patient. The mut8 phenotype observed in the heterozygous patients suggests that the second mutation involved is also of the mut8 type, although, to our knowledge, the phenotype resulting from the mut8/mut 7 compound heterozygosity has not been precisely characterised. Previous analysis of natural mut8 mutations on a homology model for human MCM has identified two types of mutations. Most of them affect a residue directly involved in catalysis, but modelling predicts that some mutations act rather by interfering with protein folding. 11 Our modelling analysis of the N219Y mutation suggests that it belongs to this second type. Indeed, substitution of Asn219 by a Tyr residue might severely influence the overall MCM conformation in different ways. First, as this residue is located in a regular secondary structure motif (end of a beta-strand within the beta-barrel), it might result in an impaired folding process of this motif and/ or in a poor structure stability. Second and most importantly, Asn219 has PHI/PSI angle values typical of left-handed helix, a conformation almost exclusively occupied by glycine and asparagine residues. Substitution by a tyrosine should therefore inhibit the formation of such particular conformation. Finally, the much bulkier and hydrophobic Tyr side chain might hamper the positioning of the adjacent helix (due to a steric clash) and lead to the disruption of the whole Nterminal beta/alpha barrel domain of the MCM molecule. The mut 7 mutations concern residues mainly located in the B 12 -binding domain. Few belong to the eight-stranded beta/alpha barrel domain but lie at the interface between these two domains that form a crevice which accommodates the adenosylcobalamin molecule. These mutations would alter the adenosylcobalamin binding. 7 Genetic heterogeneity in mut MMA is high. Since the cloning of the MUT gene in 1988 by Ledley et al, 17 at least 49 different mutations have been identified. All were reported in only one or two patients except for two (G717V and E117X) which are found in specific ethnic groups. G717V was found in four African-American and one Ghanaian MMA patients with the mut 7 phenotype, suggesting that this mutation might be ancient and of African origin. 8 E117X is a mut8 mutation and has been found with a high prevalence (24% of the alleles tested) in a group of Japanese MMA patients. 9,10 To our knowledge, no frequent mut mutation has been described to date in the Caucasian population. In our mut population (19 patients), the N219Y mutation has been found in 21% of the alleles screened. The carrier frequency is even higher (57%) among our seven mut8 patients. Four of the families in which we observed the N219Y mutation were of French descent. Screening an anonymous population of mentally retarded children living in France unexpectedly showed a 2% frequency of N219Y carriers but none were found in a similarly sized-group of normal children. As there is no reason to expect that carriership for N219Y leads to mental retardation, we can consider a global carrier frequency around 1%. This would suggest that N219Y is a frequent mutation in the French population and that the incidence of MMA in the French population is underestimated. The finding of N219Y in a Turkish family indicates that N219Y is also present in Caucasian populations from the Eastern part of the Mediterranean Basin. This could suggest an ancient origin to this mutation. Alternatively, the fact of finding the mutation on chromosome of different haplotypes may suggest independent origins to the mutation. Finer mapping of polymorphic markers around the mutation will be necessary to solve this issue.
